Canonical androstenedione reduction is the predominant source of signaling androgens in hormone-refractory prostate cancer

Clinical Cancer Research

Volumn 20, Issue 21, 2014, Pages 5547-5557

  Fankhauser, Matthew ^a   Tan, Yuen ^a   Macintyre, Geoff ^a   Haviv, Izhak ^a   Hong, Matthew K H ^a   Nguyen, Anne ^a   Pedersen, John S ^b,c   Costello, Anthony J ^a,d   Hovens, Christopher M ^a,d   Corcoran, Niall M ^a,d  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b Tissupath Pty Ltd   (Australia)

^c MONASH UNIVERSITY   (Australia)

^d Australian Prostate Cancer Research Centre at Epworth   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANDROSTENEDIONE; CHOLESTEROL; HYDROXYSTEROID DEHYDROGENASE; PRASTERONE; PREGNENOLONE; PROGESTERONE; STEROID 17ALPHA MONOOXYGENASE; TESTOSTERONE; TESTOSTERONE 17BETA DEHYDROGENASE; 15 HYDROXYPROSTAGLANDIN DEHYDROGENASE; 3(OR 17)BETA HYDROXYSTEROID DEHYDROGENASE; AKR1C3 PROTEIN, HUMAN; ANDROGEN RECEPTOR; AR PROTEIN, HUMAN; ESTRADIOL 17BETA DEHYDROGENASE;

ADULT; AGED; AKR1C3 GENE; ANDROGEN DEPRIVATION THERAPY; ARTICLE; BIOTINYLATION; CASTRATION RESISTANT PROSTATE CANCER; CATALYSIS; CONTROLLED STUDY; DISEASE COURSE; ENZYME ACTIVITY; ENZYME DEGRADATION; ENZYME SPECIFICITY; GAS CHROMATOGRAPHY; GENE OVEREXPRESSION; GENETIC VARIABILITY; GLEASON SCORE; HUMAN; HUMAN TISSUE; LEYDIG CELL; MALE; MASS SPECTROMETRY; MIDDLE AGED; ONCOGENE; POLYMERASE CHAIN REACTION; PROSTATE HYPERTROPHY; PROSTATECTOMY; PROTEIN DEGRADATION; QUANTITATIVE ANALYSIS; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; TESTOSTERONE SYNTHESIS; TISSUE LEVEL; TRANSURETHRAL RESECTION; UPREGULATION; VERY ELDERLY; METABOLISM; PHYSIOLOGY; PROSTATE; PROSTATE TUMOR;

3-HYDROXYSTEROID DEHYDROGENASES; AGED; AGED, 80 AND OVER; ANDROGENS; ANDROSTENEDIONE; ESTRADIOL DEHYDROGENASES; HUMANS; HYDROXYPROSTAGLANDIN DEHYDROGENASES; MALE; MIDDLE AGED; PROSTATE; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; SIGNAL TRANSDUCTION; UP-REGULATION;

EID: 84907393368     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-3483     Document Type: Article

References (37)

1. Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, Vessella R, et al. Molecular determinants of resistance to antiandrogen therapy. Nat Med 2004;10:33-9.
2. de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, et al. Abiraterone and increased survival in metastatic prostate cancer. N Eng J Med 2011;364:1995-2005.
3. Harris WP, Mostaghel EA, Nelson PS, Montgomery B. Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion. Nat Clin Pract Urol 2009;6:76-85.
4. Mohler JL, Gregory CW, Ford OH 3rd, Kim D, Weaver CM, Petrusz P, et al. The androgen axis in recurrent prostate cancer. Clin Cancer Res 2004;10:440-8.
5. Waltering KK, Helenius MA, Sahu B, Manni V, Linja MJ, Janne OA, et al. Increased expression of androgen receptor sensitizes prostate cancer cells to low levels of androgens. Cancer Res 2009;69:8141-9.
6. Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Eng J Med 2012;367:1187-97.
7. Mostaghel EA, Page ST, Lin DW, Fazli L, Coleman IM, True LD, et al. Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer. Cancer Res 2007;67:5033-41.
8. Chang KH, Sharifi N. Prostate cancer-from steroid transformations to clinical translation. Nat Rev Urol 2012;9:721-4.
9. Locke JA, Guns ES, Lubik AA, Adomat HH, Hendy SC, Wood CA, et al. Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer. Cancer Res 2008;68:6407-15.
10. Chang KH, Li R, Papari-Zareei M, Watumull L, Zhao YD, Auchus RJ, et al., Dihydrotestosterone synthesis bypasses testosterone to drive castration-resistant prostate cancer. Proc Natl Acad Sci U S A 2011;108:13728-33.
11. Penning TM, Burczynski ME, Jez JM, Hung CF, Lin HK, Ma H, et al. Human 3alpha-hydroxysteroid dehydrogenase isoforms (AKR1C1-AKR1C4) of the aldo-keto reductase superfamily: functional plasticity and tissue distribution reveals roles in the inactivation and formation of male and female sex hormones. Biochem J 2000;351:67-77.
12. Schänzer W, Donike M. Metabolism of anabolic steroids in man: synthesis and use of reference substances for identification of anabolic steroid metabolites. Analytica Chimica Acta 1993;275:23-48.
13. Smyth GK. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 2004;3:Article3.
14. Johnson WE, Li C, Rabinovic A. Adjusting batch effects in microarray expression data using empirical Bayes methods. Biostatistics 2007;8:118-27.
15. Hochberg Y, Benjamini Y. More powerful procedures for multiple significance testing. Stat Med 1990;9:811-8.
16. Swinnen JV, Van Veldhoven PP, Esquenet M, Heyns W, Verhoeven G. Androgens markedly stimulate the accumulation of neutral lipids in the human prostatic adenocarcinoma cell line LNCaP. Endocrinology 1996;137:4468-74.
17. Rasiah KK, Gardiner-Garden M, Padilla EJ, Moller G, Kench JG, Alles MC, et al. HSD17B4 overexpression, an independent biomarker of poor patient outcome in prostate cancer. Mol Cell Endocrinol 2009;301:89-96.
18. Lunardi A, Ala U, Epping MT, Salmena L, Clohessy JG, Webster KA, et al. A coclinical approach identifies mechanisms and potential therapies for androgen deprivation resistance in prostate cancer. Nat Genet 2013;45:747-55.
19. Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, et al. Integrative genomic profiling of human prostate cancer. Cancer Cell 2010;18:11-22.
20. Hofland J, van Weerden WM, Dits NF, Steenbergen J, van Leenders GJ, Jenster G, et al. Evidence of limited contributions for intratumoral steroidogenesis in prostate cancer. Cancer Res 2010;70:1256-64.
21. Stanbrough M, Bubley GJ, Ross K, Golub TR, Rubin MA, Penning TM, et al. Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res 2006;66:2815-25.
22. Mitsiades N, Sung CC, Schultz N, Danila DC, He B, Eedunuri VK, et al. Distinct patterns of dysregulated expression of enzymes involved in androgen synthesis and metabolism in metastatic prostate cancer tumors. Cancer Res 2012;72:6142-52.
23. Rizner TL, Penning TM. Role of aldo-keto reductase family 1 (AKR1) enzymes in human steroid metabolism. Steroids 2014;79:49-63.
24. Montgomery RB, Mostaghel EA, Vessella R, Hess DL, Kalhorn TF, Higano CS, et al. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res 2008;68:4447-54.
25. Titus MA, Gregory CW, Ford OH III, Schell MJ, Maygarden SJ, Mohler JL. Steroid 5alpha-reductase isozymes I and II in recurrent prostate cancer. Clin Cancer Res 2005;11:4365-71.
26. Russell DW, Wilson JD. Steroid 5 alpha-reductase: two genes/two enzymes. Ann Rev Biochem 1994;63:25-61.
27. Mendonca BB, Domenice S, Arnhold IJ, Costa EM. 46, XY disorders of sex development (DSD). Clin Endocrinol 2009;70:173-87.
28. Normington K, Russell DW. Tissue distribution and kinetic characteristics of rat steroid 5 alpha-reductase isozymes. Evidence for distinct physiological functions. J Biol Chem 1992;267:19548-54.
29. George FW, Russell DW, Wilson JD. Feed-forward control of prostate growth: dihydrotestosterone induces expression of its own biosynthetic enzyme, steroid 5 alpha-reductase. Proc Natl Acad Sci U S A 1991;88:8044-7.
30. Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003;349:215-24.
31. Bramson HN, Hermann D, Batchelor KW, Lee FW, James MK, Frye SV. Unique preclinical characteristics of GG745, a potent dual inhibitor of 5AR. J Pharmacol Exp Ther 1997;282:1496-502.
32. Andriole GL, Bostwick DG, Brawley OW, Gomella LG, Marberger M, Montorsi F, et al. Effect of dutasteride on the risk of prostate cancer. N Engl J Med 2010;362:1192-202.
33. Penning TM, Byrns MC. Steroid hormone transforming aldo-keto reductases and cancer. Ann NY Acad Sci 2009;1155:33-42.
34. Adeniji AO, Twenter BM, Byrns MC, Jin Y, Chen M, Winkler JD, et al. Development of potent and selective inhibitors of aldo-keto reductase 1C3 (type 5 17beta-hydroxysteroid dehydrogenase) based on N-phenyl-aminobenzoates and their structure-activity relationships. J Med Chem 2012;55:2311-23.
35. Byrns MC, Jin Y, Penning TM. Inhibitors of type 5 17beta-hydroxysteroid dehydrogenase (AKR1C3): overview and structural insights. J steroid Biochem Mol Biol 2011;125:95-104.
36. Byrns MC, Steckelbroeck S, Penning TM. An indomethacin analogue, N-(4-chlorobenzoyl)-melatonin, is a selective inhibitor of aldo-keto reductase 1C3 (type 2 3alpha-HSD, type 5 17beta-HSD, and prostaglandin F synthase), a potential target for the treatment of hormone dependent and hormone independent malignancies. Biochem Pharmacol 2008;75:484-93.
37. Chen M, Adeniji AO, Twenter BM, Winkler JD, Christianson DW, Penning TM. Crystal structures of AKR1C3 containing an N-(aryl) amino-benzoate inhibitor and a bifunctional AKR1C3 inhibitor and androgen receptor antagonist. Therapeutic leads for castrate-resistant prostate cancer. Bioorg Med Chem Lett 2012;22:3492-7.